Seres Therapeutics (MCRB) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
March 16, 2017 7:00 AM EDT- Positive SER-109 Type B FDA meeting -
- Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements -
- Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Both data read-outs expected in the second half of 2017 -
- Conference call at 8 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
Seres Therapeutics to Initiate New SER-109 Clinical Study
March 16, 2017 7:00 AM EDTPositive SER-109 Type B FDA meeting
Seres and FDA reach agreement on key design elements of a new SER-109 Phase 2 study in patients with multiply recurrent C. difficile infection
New trial may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements
Conference call at 8 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical... More
